170 / 172
170
arthritis with inadequate response to disease-modifying
antirheumatic drugs: the tocilizumab in combination with
traditional disease-modifying antirheumatic drug therapy
study. Arthritis Rheum 2008;58:2968-80.(
A
)
193.Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C,
Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor
inhibition with tocilizumab in patients with rheumatoid
arthritis (OPTION study): a double-blind, placebo-controlled,
randomised trial. Lancet 2008;371:987-97.
194.Kristensen LE, Jakobsen AK, Bartels EM, Geborek P,
Bliddal H, Saxne T, et al. The number needed to treat for
second-generation biologics when treating established
rheumatoid arthritis: a systematic quantitative review of
randomized controlled trials. Scand J Rheumatol 2011;40:1-7.
195.Schiff M, Keiserman M, Codding C, Songcharoen S,
Berman A, Nayiager S, et al. Efficacy and safety of abatacept or
infliximab vs placebo in ATTEST: a phase III, multi-centre,
randomised, double-blind, placebo-controlled study in
patients with rheumatoid arthritis and an inadequate response
to methotrexate. Ann Rheum Dis 2008;67:1096-103.
196.Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y,
Kremer J, et al. Abatacept for rheumatoid arthritis refractory to
tumor necrosis factor alpha inhibition. N Engl J Med
2005;353:1114-23.
197.Genovese MC, Schiff M, Luggen M, Becker JC, Aranda R,
Teng J, et al. Efficacy and safety of the selective co-stimulation
modulator abatacept following 2 years of treatment in patients
with rheumatoid arthritis and an inadequate response to anti-
tumour necrosis factor therapy. Ann Rheum Dis 2008;67:547-
54.
198.Kremer JM, Genant HK, Moreland LW, Russell AS, Emery
P, Abud-Mendoza C, et al. Effects of abatacept in patients with
methotrexate-resistant active rheumatoid arthritis: a
randomized trial. Ann Intern Med 2006;144:865-76.